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Basic Fibroblast Growth Factor Regulates Persistent
ERK Oscillations in Premalignant but Not Malignant
JB6 Cells
Thomas J. Weber1, Harish Shankaran2, H. Steven Wiley1, Lee K. Opresko1, William B. Chrisler1 and
Ryan D. Quesenberry1
The regulation of extracellular signal-regulated kinase (ERK) oscillations in the context of wound healing and
carcinogenesis have been investigated in premalignant and malignant JB6 mouse epidermal cells stimulated
with basic fibroblast growth factor (bFGF) and 12-O-tetradecanoyl phorbol-13-acetate (TPA). In premalignant JB6
cells, bFGF stimulation (1) increases cellular phospho-ERK and phospho-c-Jun levels, (2) increases serum-
dependent cell proliferation, (3) induces an apparent epithelial-to-mesenchymal transition, and (4) induces the
persistent nuclear–cytosolic oscillation of an ERK1–green fluorescent protein (ERK1–GFP) chimera. In contrast,
TPA induces persistent activation of ERK in the absence of oscillations and does not induce efficient migration.
Treatment of malignant or transformed JB6 cells with bFGF is associated with a transient nuclear translocation of
ERK1–GFP but not oscillations or efficient cell migration. Our data suggest that bFGF regulates ERK oscillations in
premalignant but not malignant JB6 cells.
Journal of Investigative Dermatology (2010) 130, 1444–1456; doi:10.1038/jid.2009.383; published online 17 December 2009
INTRODUCTION
Basic fibroblast growth factor (bFGF or FGF2) is a member of
the fibroblast growth factor (FGF) superfamily, comprised of
at least 23 different members (Antoine et al., 2006). bFGF is
implicated in essential processes including wound healing,
cell proliferation, differentiation, and motility (Bikfalvi et al.,
1997; Ortega et al., 1998), as well as related pathophysio-
logical processes including cancer and angiogenesis (Zhang
et al., 2003; Horstmann et al., 2005; Soufla et al., 2005). A
specific role for bFGF in cutaneous wound healing is
supported by the impaired healing of excisional wounds in
the bFGF-null mice (Ortega et al., 1998). In comparison,
epidermal wound healing appears normal in the FGF1
knockout mouse (Miller et al., 2000).
Cell signaling events induced by bFGF and other FGF
receptor (FGFR) ligands have been characterized in detail.
FGF stimulation leads to tyrosine autophosphorylation of four
high-affinity tyrosine kinase FGFRs (FGFR1–FGFR4). Signal-
ing proteins are recruited to the tyrosine autophosphorylation
sites on the activated FGFRs and link FGFR activation to
downstream pathways that regulate the proliferative response
to bFGF, including the RAS/ERK axis (Antoine et al., 2006).
bFGF stimulates a sustained ERK activation in multiple cell
types, and the duration of this signal appears to govern the
cellular response to growth factor stimulation (Antoine et al.,
2006). bFGF also frequently induces a change in cell
morphology (Kay et al., 1998).
We have investigated the regulation of cell migration,
proliferation, and ERK oscillations by bFGF in JB6 mouse
epidermal cells. JB6 cells represent a model to investigate cell
signaling as it relates to malignant transformation in skin
carcinogenesis. In addition, this model encompasses a variety
of genetic variants ranging from premalignant to fully
malignant. Our data suggest that the JB6 cells have merit
for investigating molecular features associated with cuta-
neous wound healing induced by bFGF. We also identify
oscillatory behavior in the ERK pathway that is regulated by
bFGF in the premalignant, but not malignant phenotype.
RESULTS
Basic FGF regulates cell proliferation and morphology
in vitro, and initial studies examined these responses in JB6
cells as benchmark to select optimal conditions for further
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study. Serum-starved or randomly cycling preconfluent JB6
cells were treated with 0.1–10 ngml1 bFGF for 72 hours, and
cell number was quantified using a Coulter Counter (Beckman
Coulter, Inc., Brea, CA). bFGF increased cell number in
a dose-dependent manner when added to randomly cycling
cells maintained in minimum essential medium (MEM)
supplemented with 5% fetal bovine serum (FBS), but not
when added to serum-starved cells (0.1% FBS MEM; Figure
1a). An identical trend was observed for postconfluent cells in
which bFGF stimulated a significant increase in cell number
when added to 5% FBS MEM, but not when added to serum-
starved cells (data not shown). Therefore, the proliferative
response to bFGF is serum-dependent and overrides cell–cell
contact-mediated growth inhibition in postconfluent cells.
Stimulation of JB6 cells with 10 ngml1 bFGF for
24–48 hours induced a consistent change in cell morphology
(stellate appearance; Figure 1b). This change in cell
morphology is observed in both pre- and postconfluent cells
maintained in optimal (5% FBS) or growth restrictive (0.1%
FBS) MEM (data not shown). When bFGF-treated cells
exhibiting the stellate appearance are returned to 5% FBS
MEM without bFGF, they revert to control morphology within
24–48 hours (see reverted group, Figure 1b). The change in
cell morphology resembles an epithelial-to-mesenchymal
(EMT) transition which is a developmental program char-
acterized by the loss of cell adhesion and increased cell
mobility (Savagner et al., 2005). EMT is associated with
altered expression of a number of structural proteins,
including vimentin and cytokeratins (Huang et al., 2007).
Increased vimentin and decreased cytokeratin expression in
bFGF-treated cells (Figure 1c) suggests that the observed
morphological change is consistent with EMT.
We have determined that bFGF induces a reversible
anchorage-independent growth (AIG) response in JB6 cells
(Waters et al., 2009). In this study, we investigated whether
EMT observed in monolayer culture afforded a growth
advantage on soft agar. To enable quantification of nuclei/
colony, JB6 cells (clone 41-5A) were transfected with an
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Figure 1. JB6 cell proliferation and morphological alterations induced by basic fibroblast growth factor (bFGF). (a) JB6 cells were treated with 0.1–10 ngml1
bFGF in 0.1% fetal bovine serum (FBS) minimum essential medium (MEM) (square; cells serum-starved for 24 hours before treatment) or 5% FBS (circle; cells
randomly cycling at time of treatment) for 72 hours, and cell number was quantified using a Coulter Counter. Controls were treated with vehicle (2% BSA/
phosphate-buffered saline). Values represent the mean±SE (n¼ 3). *Significantly different from respective control, Po0.05. Differential mitogenic response in
the presence and absence of serum was observed in three separate experiments, and an identical trend was observed when postconfluent cells were used (data
not shown). (b) Images of the morphological change induced by 10 ngml1 bFGF obtained by epifluorescence microscopy. Cells were fixed in methanol and
stained with SyproOrange (nonspecific fluorescent protein stain), and images were captured using a 60 oil objective and standard fluorescein filter set.
Reverted cells represent bFGF pretreated cells placed back into 5% FBS MEM for 48 hours to show the reversible regulation of cell morphology. Bar¼20 mm.
(c) Qualitative determination of vimentin and cytokeratin expression as an index of epithelial-to-mesenchymal transition in bFGF-stimulated cells upon
acquisition of the stellate morphology. Tentative cytokeratin identification is based on positive correlation between the observed molecular weight in the
western blot with the reported preference of pan-cytokeratin antibodies for specific cytokeratin polypeptides. Focal adhesion kinase was used as loading control.
Similar results were observed in two separate experiments.
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enhanced green fluorescent protein containing a nuclear
localization signal (EGFP-nuc) as described in Materials and
Methods section. JB6 EGFP-nuc cells (monolayer cultures)
were stimulated with bFGF for 48 hours, at which time the
stellate morphology was apparent (data not shown). We
included bFGF pretreated cells that were placed back into
5% FBS MEM for 48 hours, at which time the EMT phenotype
was no longer apparent (identical to experimental group
termed ‘‘reverted’’ in Figure 1b). Control, bFGF-pretreated, or
‘‘reverted’’ cells were then seeded over soft agar in the
presence of 10 ngml1 bFGF, and the representative colonies
arising at 72 hours are illustrated in Figure 2a. The bFGF-
dependent EMT phenotype was associated with a significant
growth advantage on soft agar, relative to control JB6 cells, as
reflected by an increase in the number of GFP nuclei/colony
(Figure 2b). The growth advantage associated with the EMT
phenotype was not observed when cell morphology had
reverted (Figure 2b), suggesting that the underlying molecular
basis for this growth advantage was reversible and associated
with the EMT phenotype. We have been investigating the use
of GFP variants to define AIG responses (Weber et al., 2005).
The EGFP-nuc cells were refractory to 12-O-tetradecanoyl
phorbol-13-myristate acetate (TPA)-induced AIG, yet re-
mained sensitive to bFGF-dependent AIG (Figure 2c). This
latter observation suggests that bFGF regulates a distinct AIG
program in JB6 cells, relative to TPA.
Basic FGF (10 ngml1) stimulation increased cellular
phospho-ERK (Figure 3a) and phospho-c-Jun (P-Jun; Figure
3b) levels, consistent with the ERK pathway regulating the
mitogenic response to bFGF (Izevbigie et al., 2000; Gifford
et al., 2004). bFGF can also induce a sustained activation of
the ERK pathway (Antoine et al., 2006; Krejci et al., 2007).
ERK activation was investigated at the single-cell level to
provide a detailed description of ERK dynamics under these
conditions. To accomplish this, JB6 cells were transfected
with an ERK1–GFP chimera and a monomeric red fluorescent
protein fused to a nuclear localization signal (mRFP-nuc,
used as a nuclear compartment mask; Figure 4a). bFGF and
TPA (10 ngml1 each, 5minutes) stimulated a marked
nuclear translocation of ERK1–GFP in serum-starved cells
(Figure 4b and c). Leptomycin B (LB) is an inhibitor of the
chromosomal region maintenance-1 (CRM1) nuclear export
protein (Cabot et al., 2002), which regulates ERK nuclear
export (Zuckerbraun et al., 2003). LB treatment (11 ngml1
LB, 30minutes) resulted in the accumulation of ERK1–GFP in
the nucleus (Figure 4b), suggesting that the chimera is
exported from the nucleus in a CRM1-dependent manner.
LB concentrations up to five-fold higher than required to
block nuclear export of ERK in situ did not result in detectable
levels of phospho-ERK by western blot analysis (data not
shown), indicating that LB does not directly activate ERK
under these conditions. Phosphorylation of endogenous ERKs
and the ERK1–GFP chimera stimulated by bFGF is inhibited
by 50mM PD98059 (MEK inhibitor; Figure 4d). Collectively,
these data indicate that the ERK1–GFP chimera and endo-
genous ERKs are regulated in a comparable manner.
We next followed ERK1–GFP nuclear–cytosolic shuttling in
live cells using a multispectral imaging system as described in
Materials and Methods section. ERK1–GFP cells were treated
with 10 ngml1 bFGF or 10 ngml1 TPA, images were
captured every 60 seconds for approximately 4 hours, and
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Figure 2. Epithelial-to-mesenchymal transition (EMT) affords growth
advantage on soft agar that is reversible. (a) JB6 enhanced green fluorescent
protein (EGFP)-nuc cells were treated with 10 ngml1 basic fibroblast growth
factor (bFGF) as monolayer cultures until EMT morphology was apparent.
Control or bFGF pretreated cells were then seeded over agar, treated with
10 ngml1 bFGF for 72 hours, and images of representative colonies were
captured by phase contrast or epifluorescent microscopy. (b) Quantification
of average number of EGFP nuclei/colony associated with control, bFGF
pretreated and reverted cells in the soft agar assay. Results represent the
mean±SE of the combined average of approximately 50 colonies from two
independent experiments. *Significantly different from naive control,
Po0.05. (c) Anchorage-independent growth (AIG) response of vector control
and EGFP-nuc cells to 10 ngml1 12-O-tetradecanoyl phorbol-13-acetate
(hatched) or 10 ngml1 bFGF (black), relative to respective controls (white).
Values represent the mean±SE (n¼ 3). RFOV, random fields of view.
*Significantly different from control, Po0.05. Bar¼50 mm. Similar results
were observed in two separate experiments.
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the representative single cell tracings illustrating qualitative
temporal nuclear–cytoplasmic shuttling profiles are shown in
Figure 5. For bFGF stimulation, we observe persistent
nuclear–cytoplasmic ERK oscillations. The arrow associated
with the bFGF cell tracing indicates high nuclear levels
analogous to the nuclear localization, illustrated in Figure 4b.
On the basis of the combined average of seven independent
experiments, we estimate that 57.9±4.0% (mean±SE) of
bFGF-stimulated cells exhibit ERK oscillations which are
asynchronous in the population. In contrast, TPA induced a
persistent increase in nuclear ERK levels without apparent
oscillations. This is consistent with reports demonstrating that
TPA induces a persistent activation of endogenous ERKs in
JB6 cells by western blot analysis (Suzukawa and Colburn,
2002). Control cells do not exhibit ERK oscillations (cell
tracing representative of serum-starved cells). Randomly
cycling control cells show discrete temporal fluctuations in
nuclear ERK1–GFP levels (e.g., in association with cell cycle
events, such as mitosis), but randomly cycling cells do not
exhibit ERK oscillations (data not shown). The mRFP-nuc
signal does not change significantly over time. JB6 RT101
cells are a tumorigenic genetic variant derived from TPA-
treated parental JB6 cells (Colburn et al., 1979; Takahashi
et al., 1986). RT101 cells were stably transfected with the
ERK1–GFP chimera which exhibited a transient nuclear
translocation without observable oscillations in response to
10 ngml1 bFGF stimulation (see RT101 trace; Figure 5). We
confirmed that ERK1–GFP-transfected RT101 cells grew
autonomously in soft agar (data not shown). This latter
observation is noteworthy as parallel measurements of AIG in
early passage ERK1–GFP parental JB6 cells (clone 41-5A)
demonstrate increased spontaneous transformation frequen-
cies, relative to vector controls (vector control 10.6±3.8, JB6
ERK1–GFP 55.3±6.9; colonies per 100 random fields of view
(FOV); values represent the mean±SE, n¼3). The constraints
associated with ectopic ERK expression in the JB6 model are
explained in the discussion section. See movie illustrating
ERK1–GFP oscillations induced by bFGF (Supplementary
Movie S1 online).
We quantitatively investigated the effect of bFGF con-
centration on ERK oscillation characteristics to further
understand this regulated feature. We used a waveform
classification scheme, and classified individual cells as clean
oscillators, noisy oscillators, or non-oscillators (definitions in
Materials and Methods section). The fraction of oscillating
cells increased significantly with bFGF concentration, with
the total percentage of oscillating cells (cleanþnoisy
oscillators) increasing from 5% at 0.1 ngml1 to 35% at
100 ngml1 (Figure 6a). We further analyzed the waveforms
of the clean oscillators to determine the relative amplitude,
time period, rise time, and decay time of the oscillations. The
characteristic times of the oscillations (Figure 6b, top panel)
and the oscillation amplitude (Figure 6b, bottom panel)
remained essentially unchanged with bFGF concentration.
The dose–response data set yielded an average periodicity of
16minutes, with a rise time of 7minutes and decay time of
9minutes. To quantify the overall response of the cell
population, we averaged the nuclear ERK1–GFP response of
all of the individual cells at each bFGF dose (Figure 6c).
Nuclear ERK1–GFP levels increased with bFGF dose. The
lack of a visible oscillatory pattern in the population averages
is due to the fact that the oscillations of individual cells are
not synchronized; therefore, oscillatory behavior cannot be
resolved in an averaged measurement of the population.
Collectively, our data indicate that the fraction of oscillating
cells and the nuclear ERK levels of the population increase
with bFGF dose while the oscillation characteristics them-
selves remain unchanged.
To quantify the magnitude of the oscillatory response, we
computed the oscillation amplitude as described in Materials
and Methods section. At 10 ngml1 bFGF, the oscillation
amplitude averaged across multiple oscillating cells is B180
fluorescence units when expressed as the difference between
the peaks and the valleys in the oscillation profile. Nuclear
ERK levels associated with functional responses to bFGF
(Figure 6c) display an increase of B200 fluorescence units
when comparing low and high bFGF concentrations. Nuclear
ERK–GFP levels are quantified under conditions where they
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Figure 3. Activation of the extracellular signal-regulated kinase (ERK)
pathway in basic fibroblast growth factor (bFGF)-stimulated JB6 cells.
Serum-starved JB6 cells were stimulated with 10 ngml1 bFGF for
5–30minutes and levels of phospho-ERK (a) and phospho-Jun (20minutes; b)
were determined by western blot and in situ, respectively. Values represent
the mean±SE for approximately 100 cells as described in Materials and
Methods section. *Significantly different from control, Po0.05. RFU, relative
fluorescence units. Bar¼20 mm. Similar results were observed in three
separate experiments.
www.jidonline.org 1447
TJ Weber et al.
Regulated ERK Oscillations
are competing (both nuclear import and export) with
endogenous ERK levels and are, therefore, likely under-
estimates of the true fraction of oscillating ERK. Although it is
difficult to exactly quantify the fraction of total cellular ERK
that oscillates, we conclude that the absolute oscillation
amplitude is in the biologically relevant range.
We next compared cell migration under conditions
associated with persistent ERK oscillations (bFGF) versus
persistent ERK activation (TPA). A scratch wound was
induced in vitro using a pipette tip and cells were then
treated with 10 ngml1 bFGF or 10 ngml1 TPA for 24 hours
in 0.25% FBS MEM as described in Materials and Methods
section. bFGF treatment promoted efficient cell migration
and closure of the scratch wound, while TPA was marginally
active in side-by-side comparisons (Figure 7a). As bFGF does
not induce cell proliferation at low serum concentrations (see
Figure 1), in vitro wound healing primarily reflects cell
migration under these conditions. The wound size was
measured at defined intervals, and linear regression analysis
was used to estimate the rates of wound closure from the
plotted data, as described in Materials and Methods section
(Figure 7b, lower panel). Scratch-wound closure rates for
DMSO-, bFGF-, and TPA-treated cells were 2.54±0.23,
7.35±1.12, and 3.63±1.21, respectively (values represent
mmhour1±SE; n¼ 4). In contrast, stimulation of malignant
RT101 cells with bFGF or TPA under identical conditions did
not result in an efficient cell migration response (Figure 7a,
RT101 panel).
Malignant RT101 cells do not exhibit ERK oscillations or
efficient cell migration in response to bFGF (see Figure 7),
although transient activation of ERK was observed (see RT101
trace in Figure 5).We subsequently investigated bFGF-dependent
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Figure 4. Extracellular signal-regulated kinase–green fluorescent protein (ERK1–GFP) chimera and endogenous ERKs exhibit comparable patterns of regulation
in JB6 cells. (a) JB6 cells were stably transfected with an ERK1–GFP chimera and mRFP-nuc as described in Materials and Methods section. Bar¼ 20mm.
(b) Treatment of ERK1–GFP JB6 cells with basic fibroblast growth factor (bFGF) (10 ngml1, 5minutes), 12-O-tetradecanoyl phorbol-13-acetate (TPA)
(10 ngml1, 5minutes), or leptomycin B (LB) (11 ngml1, 30minutes) was associated with a marked nuclear localization of the ERK1–GFP chimera, relative to
vehicle-treated control. Bar¼ 20mm. (c) Peak nuclear ERK1–GFP levels were comparable in cells treated with a maximal concentration of bFGF (10 ngml1,
white) and TPA (10 ngml1, black), as reflected by the nuclear/cytosolic ERK1–GFP ratio. Values represent the mean±SE for approximately 100 cells.
*Significantly different from control, Po0.05. Similar results were observed in three separate experiments. (d) Treatment of serum-starved JB6 cells with
10 ngml1 bFGF for 5minutes resulted in a marked increase in the levels of phosphorylated endogenous ERKs and the ERK1–GFP chimera and these events were
inhibited by pretreatment with the MEK inhibitor PD98059 but not DMSO. Similar results were observed in two separate experiments.
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cell migration in several JB6-transformed genetic variants to
confirm the differential regulation of this response in the
transformed phenotype. Transformed variants used in these
experiments are characterized as possessing autonomous AIG
properties and included JB6 cells transfected with hepatic
leukemia factor, D-site albumin promoter-binding protein
and TPA-treated ERK1–GFP cells (cells were selected from
soft agar assay, established as independent cell lines and
were characterized for autonomous AIG properties). In all the
cases, the transformed variant did not exhibit an efficient cell
migration response to bFGF, relative to the premalignant
counterpart (data not shown), consistent with our original
observation illustrated in Figure 7.
We performed a number of supporting experiments to
understand specificity in the regulation of ERK oscillations
that are summarized in Table 1 and in text. The physical
damage to cell monolayers induced by a scratch wound is
associated with the activation of the ERK pathway (Fitsialos
et al., 2007). In postconfluent JB6 cells, a scratch wound
induces the transient nuclear translocation of ERK1–GFP,
without observable oscillations (Table 1). Adenosine tripho-
sphate is released into the medium following wounding
in vitro and activates purinergic receptors coupled to the ERK
pathway (Yin et al., 2007). Stimulation of JB6 cells with a
non-hydrolyzable adenosine triphosphate analog (adenosine
triphosphategS; 10 mM) is associated with a transient nuclear
translocation of ERK1–GFP, but not oscillations (Table 1).
FGF1 is reported to bind to all known FGFRs (Ornitz et al.,
1996). Treatment of JB6 cells with 10 ngml1 FGF1 induces a
transient nuclear translocation of ERK1–GFP, but not oscilla-
tions, efficient cell migration, or a cell shape change (ERK
data in Table 1; migration and shape change data not shown).
FGF1 was biologically active in JB6 cells and increased cell
proliferation in a dose-dependent manner (control, 100±0.7;
0.1 ngml1 FGF1, 117±5, 1 ngml1 FGF1, 153±4,
10 ngml1 FGF1, 183±7; values represent the mean±SE
illustrated as % control, n¼3, similar results were observed
in two separate experiments). AIG was also increased by
FGF1, although this response was marginal (control, 24±4;
FGF1, 53±5; values represent the mean number of colonies
per 100 RFOV±SE, n¼3, similar results were observed in
three separate experiments). Treatment of JB6 cells with
0.1–100 ngml1 FGF7, FGF10, and FGF22 did not induce
ERK1–GFP nuclear translocation, ERK oscillations, or efficient
cell migration (Table 1). Therefore, ERK oscillations are not a
general feature of this model, but rather, represent a regulated
feature associated with bFGF stimulation.
DISCUSSION
Basic FGF is implicated in cutaneous wound healing (Ortega
et al., 1998) but has not shown significant potential as a
tumor promoter in the skin (Vassar et al., 1992; Tanaka et al.,
3,000
2,000
1,000
bFGF TPA 
0
3,000
2,000
1,000
0
0 90 180 270 360
N
uc
le
ar
 E
R
K–
G
FP
 le
ve
l
(R
FU
 pe
r n
uc
leu
s)
Control
3,000
2,000
1,000
0
0 90 180 270 360
mRFP
Time (min)
3,000
2,000
1,000
0
0 90 180 270 360
0 90 180 270 360
RT101
3,000
2,000
1,000
0
0 90 180 270 360
Figure 5. Qualitative temporal extracellular signal-regulated kinase (ERK) nuclear-cytoplasmic shuttling profiles in premalignant and malignant JB6 cells.
Premalignant JB6 cells (clone 41-5A) are represented by the basic fibroblast growth factor (bFGF), 12-O-tetradecanoyl phorbol-13-acetate (TPA), control, and
mRFP-nuc cell tracings. Malignant JB6 RT101 cells are represented by the RT101 cell tracing. JB6 cells were stimulated with 10ngml1 bFGF or TPA, and nuclear
ERK1–GFP levels were measured every 60 seconds for approximately 4hours using a multispectral imaging system as described in Materials and Methods section.
The oscillatory behavior in the ERK pathway was selectively associated with bFGF-stimulated cells and was observed in seven independent experiments.
In malignant JB6 RT101 cells, bFGF induced a transient nuclear translocation of ERK1–GFP without observable oscillations. RFU, relative fluorescence units.
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1996). In this study, we establish that bFGF regulates EMT,
AIG, serum-dependent proliferation, and cell migration in
JB6 cells. Collectively, the reversible nature of these
responses in vitro taken together with the function of bFGF
in wound healing but not tumor promotion in vivo provide a
rationale for interpreting the regulation of epidermal cells by
bFGF in a wound-healing context. ERK oscillations have not
previously been reported for the bFGF pathway.
Independent investigators have demonstrated that the low-
molecular-weight form of bFGF is poorly mitogenic under
low serum conditions (Bikfalvi et al., 1995) and our data are
consistent with this observation (Figure 1a). Under low serum
conditions, we observe EMT (Figure 1c) and an associated
increase in cell migration (Figure 7). Therefore, bFGF-
dependent cell migration can be preferentially investigated
at low serum concentrations. The induction of EMT, AIG, and
inhibition of cell–cell contact-mediated growth arrest by
bFGF (Figures 1 and 2) likely creates a permissive environ-
ment for growth factor responsiveness, which would account
for the requisite role of serum in this response.
Suppression of ERK activity correlates with the suppression
of cell migration in human keratinocytes (Neill et al., 2008).
In our studies, bFGF induces cell migration and ERK
oscillations, raising the possibility that the ERK oscillations
contribute to migration or perhaps simply reflect a migration-
competent phenotype. In contrast, EGF does not induce ERK
oscillations or efficient cell migration in JB6 cells, which
contrasts the regulation of cell migration by EGF in normal
human keratinocytes (Hudson and McCawley, 1998). This
latter observation suggests a defect in the JB6 EGF pathway,
as EGF does not induce efficient cell migration under the
conditions used here. However, the lack of EGF-dependent
cell migration did correlate with a lack of EGF-dependent
ERK oscillations as well. Thus, if ERK oscillations contribute
to cell migration, then EGF is expected to induce both cell
migration and ERK oscillations in normal human keratino-
cytes, a hypothesis awaiting experimental validation.
Basic FGF induces EMT and AIG in JB6 cells and these
responses are dependent on persistent exposure to ligand, as
cells revert to the control phenotype if ligand is removed
from the system (e.g., see Figure 1b). The persistence of ERK
oscillations stimulated by bFGF argues that the signaling
pathway coupled to bFGF stimulation is not rapidly down-
regulated, a feature that is desirable in a wound-healing
context. Persistent bFGF stimulation of cutaneous cells could
arise from multiple sources during wounding, including the
release of bFGF sequestered in extracellular matrix (Ishai-
Michaeli et al., 1990), cellular synthesis of bFGF in response
to inflammation (Vagner et al., 1996; Blackburn et al., 1999;
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Figure 6. Effect of basic fibroblast growth factor (bFGF) concentration on
extracellular signal-regulated kinase (ERK) oscillation characteristics. JB6
cells were stimulated with 0.1–100 ngml1 bFGF, and the nuclear ERK–GFP
waveforms of individual cells were quantitatively analyzed to determine ERK
oscillation characteristics. The responses of B100 individual cells were
analyzed at each bFGF concentration. The percentage of clean oscillators and
the total percentage of oscillating cells (clean þ noisy oscillators) were
determined using a waveform classification scheme as described in Materials
and Methods section. (a) Percentage of total and clean oscillations is plotted
as a function of bFGF concentration. (b) The waveforms of the clean
oscillators were analyzed to obtain time periods, rise times, decay times, and
oscillation amplitudes. The characteristic times of the oscillations (top panel:
solid circle, time period; solid square, rise time; open square, decay time);
and the normalized oscillation amplitude (bottom panel) is plotted as a
function of bFGF concentration. Values represent the mean±SD obtained
from multiple cells. (c) The population-averaged nuclear ERK1–GFP response
at different bFGF concentrations. The waveforms of all individual cells,
including oscillators and non-oscillators, were averaged to obtain the average
profiles. For each ligand concentration, the mean ERK1–GFP level before
ligand addition was subtracted from the profile to place the responses on the
same scale. Although the fraction of oscillating cells and the population
ERK–GFP response increase with bFGF concentration, the periodicity and
amplitude of the oscillations remain unchanged.
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Table 1. Extracellular signal-regulated kinase (ERK) oscillations are a regulated feature of basic fibroblast growth
factor (bFGF) signaling in JB6 cells and not a general feature associated with ERK activation
Stimulus Transient ERK nuclear translocation ERK oscillations Efficient cell migration
10 ngml1 Endothelial growth factor Yes No No
Scratch wound Yes No ND
10 mM Adenosine triphosphate Yes No ND
0.1–100 ngml1 FGF1 Yes No (100 ngml1) No
0.1–100 ngml1 FGF7 No No (100 ngml1) No
0.1–100 ngml1 FGF10 No No (100 ngml1) No
0.1–100 ngml1 FGF22 No No (100 ngml1) No
Abbreviation: ND, not determined.
JB6 cells were stimulated with a variety of agents that couple to ERK activation in diverse model systems. Transient nuclear translocation of ERK was
observed in the absence of oscillations, indicating this complex pattern of kinase behavior was a regulated feature of bFGF signaling. Additional FGF
receptor ligands that were tested were not functional in the JB6 model for both activation of ERK and regulation of cell migration.
JB6 41-5A
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Figure 7. Basic fibroblast growth factor (bFGF), but not 12-O-tetradecanoyl phorbol-13-acetate (TPA), promotes efficient cell migration in premalignant
cells, and bFGF-dependent cell migration is not observed in malignant cells. (a) Monolayers were scratched with a 20ml pipette tip followed by treatment with
10 ngml1 bFGF or 10 ngml1 TPA for 24 hours. Images represent in vitro wound at 24 hours. JB6 clone 41-5A represents the premalignant phenotype,
and RT101 represents the malignant phenotype. (b) Images were captured at defined time intervals, the wound size was measured, and linear regression analysis
was used to estimate scratch-wound closure rates for clone 41-5A cells as described in Materials and Methods section. Values represent the mean±SE (n¼ 3).
Similar results were observed in three separate experiments.
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Spitz et al., 2000; Wada et al., 2001), secretion by fibroblasts
(Aktas and Kayton, 2000), and in response to cytokines such
as tumor necrosis factor-a (Ono et al., 1999). In addition,
sustained delivery of growth factors might be an important
determinant of wound healing (Hom et al., 1996). Incorpora-
tion of bFGF into hydrogel formulations designed to
accommodate sustained delivery improves dermis formation
and vascularization in experimental models (Liu et al., 2007).
If the linkage between EMT/AIG regulation by bFGF and
serum-dependent proliferation is conserved in vivo, then it is
possible that the efficacy of bFGF in wound healing may be
improved by developing appropriate combinatorial growth
factor formulations.
Although ERK oscillations are remarkable for their
persistence and regularity, how they encode the information
that can cause different cellular responses remains to be
established. ERK is a potent activator of many nuclear
transcription factors, and oscillations could be a means to
selectively activate a subset of ERK-responsive genes,
analogous to oscillatory calcium signaling (Zhu et al.,
2008). However, in the case of calcium oscillations,
information about stimulus dose can be encoded both in the
amplitude and frequency of oscillations, which in turn control
the level and specificity of gene expression (Dolmetsch et al.,
1998). Unlike calcium oscillations, ERK oscillations do not
display strong frequency or amplitude modulation in response
to ligand dose. In this sense, ERK oscillations display switch-
like characteristics with cells either being non-oscillatory or
oscillating with a fixed frequency and amplitude. Increasing
bFGF concentration increases nuclear ERK levels and switches
more cells to an oscillatory state, thereby increasing the
fraction of cells in which the oscillation-mediated responses
are induced, which may reflect cellular regulation as a
function of signal strength. We have recently defined global
gene expression profiles in JB6 soft agar colonies induced by
bFGF and TPA (Waters et al., 2009). Our findings clearly
demonstrate that bFGF and TPA induce largely non-over-
lapping gene expression profiles that are associated with the
reversible and irreversible AIG phenotypes, respectively. These
observations are consistent with the data presented here, in
which we demonstrate that TPA differentially regulates ERK
activation (persistent activation without oscillations, Figure 5)
relative to bFGF (oscillations) and TPA does not induce
efficient cell migration in premalignant cells. Furthermore,
bFGF, but not TPA, induces AIG in EGFP-nuc cells (Figure 2).
Collectively, these observations support the notion that
bFGF and TPA regulate distinct cellular programs in JB6 cells,
which mirror their roles in cutaneous wound healing and
carcinogenesis, respectively.
Recently, bFGF has been shown to induce oscillatory
behavior in the Ras/ERK pathway culminating in the
regulation of Hes1 gene expression in fibroblast cell lines
(C3H 10T1/2; NIH 3T3) (Nakayama et al., 2008). Oscillations
are induced by bFGF with approximately 2 hours cycle times
in a synchronized manner and the oscillation pattern
correlates with Hes1 gene expression. Serum also induces
Hes1 oscillations under these conditions. In contrast, JB6
cells display persistent ERK oscillations with a periodicity of
16minutes that are asynchronous, and ERK oscillations are
not induced by serum. In our microarray experiment, bFGF
treatment is associated with decreased Hes1 expression
(approximately 1.5-fold) (Waters et al., 2009). Therefore,
ERK oscillations and associated cellular programming are
distinct in the JB6 and fibroblast model systems.
JB6 cells are an immortalized epidermal cell line that
was originally developed to investigate the mechanisms
of tumor promotion (Colburn et al., 1979). We hypothesize
that this model can also provide important insight into
the molecular basis of wound healing regulated by bFGF. In
support of this interpretation, bFGF-null mice have
showed delayed healing when challenged by full-thickness
excisional wounds (Ortega et al., 1998), whereas
epidermal wound healing appears normal in the FGF1
knockout mouse (Miller et al., 2000). Our data reflect this
dichotomy in that bFGF regulates ERK oscillations, EMT,
efficient cell migration, and AIG in JB6 cells, which have
plausible implications in the wound-healing process,
whereas FGF1 does not induce ERK oscillations or cell
migration in this model. Furthermore, bFGF regulates JB6
function in a reversible manner, which mirrors the reversible
nature of wound healing in vivo.
Epithelial-to-mesenchymal transition is a reversible devel-
opmental program that promotes cell motility but is also
associated with the invasive program of tumor cells. These
observations share the central feature of increased cell
migration, which is consistent with the observed EMT
phenotype associated with efficient cell migration reported
here (Figures 1 and 7). Increased vimentin expression in
bFGF-stimulated cells was used to support our interpretation
of the EMT phenotype (Figure 1). Vimentin is typically
expressed in mesenchymal cells, but not normal epithelial
cells and we conducted a literature search to determine
whether vimentin expression was apparent in normal
epithelial cells in a wound-healing context. In summary,
the primary human keratinocytes stain positively for cytoker-
atin as a marker of epithelial cells, but also stain positively for
vimentin (Van Muijen et al., 1987), and there are many
examples of normal epithelial cells grown in vitro that
express both cytokeratin and vimentin (Haake and Lane,
1989; Richard et al., 1990; Pieper et al., 1992). Increased
vimentin expression is believed to reflect the transition to a
proliferative or activated phenotype in vitro. Epidermal organ
explants are used as a bridge between in vitro and in vivo
model systems, and normal keratinocytes at the leading edge
of outgrowths from these explants express vimentin (Biddle
and Spandau, 1996). Wound healing in experimental animal
models, including the use of human skin grafted onto the
back of mice (Demarchez et al., 1987; Windsor et al., 2009)
and keratinocytes/dermal fibroblasts cultured on polymer
scaffolds (Kim et al., 2005), are associated with increased
vimentin expression in the human epidermis and neodermis.
Where examined, vimentin expression is markedly reduced
in the epidermis as the wound resolves (Demarchez et al.,
1987). Finally, cell migration is significantly impaired in the
vimentin knockout mouse (Eckes et al., 2000). Collectively,
these observations provide a plausible connection between
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increased vimentin expression and cell migration in epithelial
cells that is consistent with a wound-healing context.
Finally, ERK has a pivotal role in regulating malignant
transformation of JB6 cells (Huang et al., 1998). We have
observed that ERK1–GFP transfectants become transformed
with increased passage. Enhanced transformation limits the
lifetime of this model as the transformed variant does not
exhibit ERK oscillations or efficient cell migration in response
to bFGF stimulation (Figures 5 and 7). However, this event is
manageable within the experimental framework as the
transformed variants can be replaced with early passage cells
when spontaneous transformation frequencies are elevated
(460 colonies per 10,000 cells in soft agar assay). The
transformed variant is also removed from analysis by default
because of the lack of ERK oscillations and cell migration in
response to bFGF.
In summary, bFGF stimulation leads to increases in cell
proliferation, EMT, AIG, and migration in JB6 cells that are
interpreted in a wound-healing context and are differentially
regulated in premalignant and malignant phenotypes. ERK
oscillations have not previously been reported for the bFGF
axis and represent an additional complexity associated with
kinase systems in vivo.
MATERIALS AND METHODS
Materials
Human recombinant bFGF, aFGF, lipofectamine, and Alexa 488-
conjugated secondary antibodies were purchased from Invitrogen
(Carlsbad, CA). Living Colors Vectors pEYFP-membrane and pEGFP-
nuc were from Clontech (Palo Alto, CA). Anti-phospho-ERK antibody
was from Promega (Madison, WI). Antibodies against ERK1, ERK2,
phospho-Jun, and vimentin were from Santa Cruz Biotechnology
(Santa Cruz, CA). All other reagents were from Sigma Chemical
(St Louis, MO).
Cell culture
JB6 cells (clone 41-5a and RT101) were maintained in MEM
supplemented with 5% FBS 2mM L-glutamine, 100Uml1 penicillin,
100mgml1 streptomycin, and 25mgml1 amphotericin B in 5%
CO2/95% air at 37 1C. Cells were subcultured by trypsinization.
Stock cultures of clone 41-5A cells were maintained at precon-
fluence and were discarded when background spontaneous trans-
formation frequencies were above 60 colonies per 10,000 cells in
the soft agar assay. In select experiments, postconfluent JB6 cultures
were used to investigate bFGF-dependent proliferation, and all
experimental groups were discarded upon termination of the
experiment to prevent drift in the ratio of transformed to
premalignant cells that could occur with the growth advantage
afforded transformed cells at high densities.
Cell proliferation assays
For serum-starved groups, cells were incubated in 0.1% FBS MEM
for 24 hours followed by treatment with bFGF at the indicated
concentrations in 0.1% FBS MEM for 72hours. For randomly cycling
groups, cells were maintained and treated with bFGF in 5% FBS
MEM. For both experimental groups, cells were seeded in 24-well
plates at an equal density and cell number was determined using a
Coulter Counter.
Transfection of JB6 cells with Living Colors Vectors
JB6 cells were transfected with Living Colors Vectors containing
membrane-localized enhanced yellow fluorescent protein
(enhanced yellow fluorescent protein-membrane) or nuclear loca-
lized EGFP (EGFP-nuc) as previously described (Weber et al., 2005).
In brief, vectors were transfected using lipofectamine reagent and
stable transfectants were selected by neomycin resistance
(800mgml1). Cells stably expressing GFP variants were isolated
by FACS.
Western blot analysis
Western blot analysis was performed as previously described (Weber
et al., 2002). Anti-cytokeratin antibodies were used to aid in the
differentiation between the epithelial (keratin-positive) and me-
senchymal (keratin-negative) phenotype. Cytokeratins were detected
using pan-cytokeratin antibodies that detect multiple polypeptides.
On the basis of the manufacturer’s specifications, these antibodies
(monoclonal anti-cytokeratin 8.12, 8.13, and 4.62; Sigma Chemical,
St Louis, MO) are expected to exhibit preferences with regard to the
specific subset of cytokeratins detected (cytokeratins 9, 10, 11, 13,
15, 16, 18, 19). Tentative identification of cytokeratins is based on
positive correlation between the observed molecular weight of
cytokeratins in western blot experiments and reported preferential
affinity of cytokeratin antibodies for specific polypeptides reported
by the manufacturer.
Quantification of nuclear P-Jun levels
JB6 cells were fixed in 3.6% paraformaldehyde/0.024% saponin for
15minutes at room temperature for in situ analysis of nuclear P-Jun
levels. Following fixation, cells were washed three times with
phosphate-buffered saline (PBS) and permeabilized with PBS/0.2%
Triton X-100 for 5minutes with gentle rocking. Cells were then
blocked in PBS supplemented with 2% BSA and 5% normal goat
serum for 1 hour. Cells were exposed to anti-P-Jun antibody (1:3000)
in PBS/2% BSA for 1 hour at room temperature with gentle rocking.
Following incubation with primary antibody, cells were washed
three times with PBS/2% BSA and were then incubated with Alexa
488-conjugated anti-mouse secondary antibody (1:5000) for 1 hour.
Cells were then incubated with 1 mM 4,6-diamidino-2-phenylindole
for 5minutes followed by three washes (5minutes each) with PBS/
2% BSA and analysis of nuclear P-Jun levels by epifluorescence
microscopy as previously described (Weber et al., 2005).
4,6-diamidino-2-phenylindole-stained nuclei were used to create a
mask to quantify nuclear P-Jun levels in control and bFGF-treated
cells using Metamorph image processing software (Universal
Imaging, Media, PA). Equal exposure times were used for control
and bFGF-treated groups in all cases. Background was subtracted
from all images and results are expressed as the average relative
fluorescence units per nucleus.
Establishment of ERK1–GFP stably transfected cells
Human mitogen-activated protein kinase 1 or ERK1 (GenBank
accession no. NM-002745) was fused in-frame with eGFP (pEGFP-
C1; Clontech, Mountain View, CA) at the amino-terminus and
subsequently subcloned into the retroviral vector pBM-IRESpuro
(Garton et al., 2002). The resulting plasmid, pBM-GFP-ERK1,
was introduced into JB6 mouse epidermal cells using retroviral
transduction. Virus-containing medium was collected from Phoenix
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cells transiently transfected with pBM-ERK1-GFP (Kitamura et al.,
1995). JB6 cells were incubated in medium containing virus and
4mgml1 polybrene for 7 hours, and then incubated for 2 days
before selection in puromycin (2 mgml1). Cells stably expressing
ERK1–GFP were maintained in normal growth medium supple-
mented with puromycin.
In vivo confocal and epifluorescence microscopy
Cells expressing ERK1–GFP and mRFP-nuc were seeded at varying
densities onto 24-well Sensoplate coverlip (Greiner Bio-One,
Monroe, NC) and allowed to attach for 4 hours. After 4 hours, the
cells were washed and then incubated overnight with MEM
(Invitrogen) containing 0.3% FBS. Prior to imaging, the media was
replaced with 2ml Leibovitz’s L-15 Medium (Invitrogen) containing
0.3% FBS. The cells were then placed onto a Nikon Eclipse TE300
inverted microscope (Melville, NY) equipped with an environment
chamber (In Vivo Scientific, St Louis, MO) maintained at 37 1C
and allowed to equilibrate 1 hour before imaging. Three random
fields in each well were selected for imaging in both the GFP and
mRFP excitation and emission every 60 seconds using a Nikon Plan
APO 20 /0.75 objective using an Retiga 1300 cooled CCD
(QImaging, Surrey, BC, Canada) controlled by Volocity Acquisition
(Improvision, Waltham, MS) software. bFGF was added in a 20 ml
volume to achieve the desired final concentration.
Image analysis to determine the nuclear ERK concentration
profile in individual cells
Epifluorescence images of mRFP-tagged nuclei (red channel) were
analyzed using the tracking utility in the Volocity software to track
the locations of individual cell nuclei during the time course of the
experiment. Nuclei were identified in the red channel using the SD
Intensity function (2–100 limits), a medium noise filter, separating
touching objects (size 0.1 mm2), and a pixel count of 4100.
Cell nuclei tracks starting from time t¼ 0 and containing at least
150 continuous frames (total tracking timeB150minutes) were used
for subsequent analysis. The mean ERK1–GFP (green channel)
intensity was measured in the regions occupied by the selected cell
nuclei in each of the time frames. These measurements resulted in
continuous nuclear ERK fluorescence versus time curves for
individual cells.
Quantitative analysis of ERK oscillations
We used Fourier transformation to estimate the frequency compo-
nent of the oscillations associated with each cell. By inspecting the
waveforms in the time and frequency domain, we could classify cells
as ‘‘clean’’ oscillators, with a single, strong frequency component
and a continuous train of at least 10 oscillations in the time domain;
‘‘noisy’’ oscillators that display intermittent or very low amplitude
oscillations, but with the Fourier transformation spectrum showing a
clear peak in the 103 to 2 103Hz range; and non-oscillators with
no dominant peak in the Fourier transformation spectrum. Time
domain analysis of the clean oscillators enabled us to quantify the
time period, rise time, decay time, and the oscillation amplitude. The
locations of the peaks and valleys in the time series were first
automatically determined by identifying points of inflection in a
piecewise quadratic fit of the data. Parabolic curves were fitted to
the time series 5 points at a time. A strong extrema in the time series
appeared as inflections in successive piecewise fits and were
retained. The locations of these extrema were further filtered to
ensure that the time series contained alternating sets of peaks and
valleys. If there were two successive peaks (or valleys) in the time
series, then the highest (lowest) of these peaks (valleys) was retained.
The ith pulse in the oscillation series comprises the valleys tv(i) and
tv(iþ 1) and has an intermediate peak at tp(i). We computed the time
period of the ith pulse as Ti¼ tv(iþ 1)–tv(i). In addition, we computed
the rise and decay times for this pulse as Ri¼ tp(i)–tv(i) and
Di¼ tv(iþ 1)–tp(i). Once the time period and rise and decay times
were obtained for all the pulses in the time series, the results were
combined to determine the average values (oRi4, oDi4, oTi4)
of these quantities for each cell. In order to compute the amplitude,
we determined the response value at the midpoint times in the rise
and decay phases of each pulse to obtain estimates of how the mean
ERK–GFP level, Ymean(t) changed as a function of time. We fitted a
piecewise cubic polynomial through the Ymean versus t curve to
enable interpolation. The amplitude of each pulse was determined as
the difference between the actual nuclear ERK–GFP level and the
estimated Ymean value at the pulse peak, i.e., Ai¼ y(tp(i))–Ymean(tp(i)).
We computed a normalized amplitude Ai
* for each pulse as Ai
*¼Ai/
Ymean(tp(i)). We averaged these normalized pulse amplitudes to
obtain a mean amplitude oAi*4 value for each cell.
In vitro wound assay
JB6 cells were seeded onto six-well cell culture plates (BD Falcon,
San Jose, CA) and allowed to grow to confluency under optimal
growth conditions. Before imaging, a single scratch was made using
a 20 ml pipette tip (Rainin, Oakland, CA). The medium was then
aspirated and replaced with 2ml DFHB medium (50% minimum
essential medium, 50% F-12 nutrient medium, 1% bovine serum
albumin, 2 mM L-glutamine, no sodium bicarbonate) supplemented
with 0.25% FBS and 20mM (4-(2-hydroxyethyl)-1-piperazineetha-
nesulfonic acid) (pH 7.4) with or without 10 ngml1 bFGF or TPA.
The cells were then placed onto a Nikon Eclipse TE300 inverted
microscope equipped with an environment chamber (In Vivio
Scientific, LLC) maintained at 37 1C. Four random FOV along each
individual scratch were selected and the same FOV was sequentially
imaged in brightfield every 10minutes using a Nikon Plan APO 4X/
0.2 objective using a Retiga 1300 cooled CCD camera (QImaging)
and automated stage (Ludl Electronic Products, Hawthorne, NY)
controlled by Volocity Acquisition (Improvision) software. Closure of
the experimental scratch wound was measured using the Line Tool
function in Volocity. For each FOV, 10 individual lines were placed
across the wound at the leading edge of the cell (field of view
902050¼mm2). The width of each individual line was measured
every 2 hours over the time course and lines were manually adjusted
to touch the leading edge of the cell at each end of the scratch.
Therefore, individual data points represent the average of 4 FOVs,
each of which reflect the average scratch diameter derived from 10
individual lines. The plotted data were used to determine the closure
rate. It is noteworthy that the closure rates are sensitive to the
concentration of FBS used in the experiment. Specifically, closure
rates in control cells maintained in 0.25% FBS medium versus 0.5%
FBS medium were 2.54±0.23 vs 5.21±0.93 (mmhour1±SE),
respectively, and closure rates associated with bFGF- and
TPA-treatment were increased proportionally in medium supple-
mented with 0.5% FBS (data not shown). From a practical
perspective, low concentrations of FBS (0.2–0.5%) were optimal to
1454 Journal of Investigative Dermatology (2010), Volume 130
TJ Weber et al.
Regulated ERK Oscillations
observe differences in the scratch-wound closure rate between
bFGF-stimulated cells, relative to controls.
Statistics
Individual comparisons were carried out using Student’s t-test or
analysis of variance with a post hoc Student’s Newman–Keul test, as
appropriate. The Po0.05 level was accepted as significant.
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